152 related articles for article (PubMed ID: 35993247)
1. Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic
Suh K; Carlson JJ; Xia F; Williamson T; Sullivan SD
J Comp Eff Res; 2022 Oct; 11(14):1011-1019. PubMed ID: 35993247
[No Abstract] [Full Text] [Related]
2. The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer.
Roth JA; Carlson JJ; Xia F; Williamson T; Sullivan SD
J Manag Care Spec Pharm; 2020 Aug; 26(8):981-986. PubMed ID: 32329651
[TBL] [Abstract][Full Text] [Related]
3. The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma.
Suh K; Carlson JJ; Xia F; Williamson T; Sullivan SD
J Manag Care Spec Pharm; 2022 Jun; 28(6):622-630. PubMed ID: 35362337
[No Abstract] [Full Text] [Related]
4. Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer.
Carlson JJ; Italiano A; Brose MS; Federman N; Lassen U; Kummar S; Sullivan SD
Am J Manag Care; 2022 Jan; 28(2 Suppl):S26-S32. PubMed ID: 35201681
[TBL] [Abstract][Full Text] [Related]
5. Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers.
Garcia-Foncillas J; Bokemeyer C; Italiano A; Keating K; Paracha N; Fellous M; Marian M; Fillbrunn M; Gao W; Ayyagari R; Lassen U
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406565
[TBL] [Abstract][Full Text] [Related]
6. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
[TBL] [Abstract][Full Text] [Related]
7. [Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion].
Delaye M; Rodrigues M
Bull Cancer; 2020 Nov; 107(11):1085-1086. PubMed ID: 33169692
[No Abstract] [Full Text] [Related]
8. A RESPONSE TO "THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER".
Ogale S; Zerbini CEH; Antoniou M; Freund R
J Manag Care Spec Pharm; 2020 Dec; 26(12):1616-1617. PubMed ID: 33251994
[No Abstract] [Full Text] [Related]
9. Evolving role of entrectinib in treatment of
Chawla N; Bui NQ; Seetharam M
Future Oncol; 2021 Aug; 17(22):2835-2846. PubMed ID: 33896226
[TBL] [Abstract][Full Text] [Related]
10. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?].
Ouali K; Pellat A; Cohen R; Svrcek M; Penault-Llorca F; André T
Bull Cancer; 2020 Apr; 107(4):447-457. PubMed ID: 32067719
[TBL] [Abstract][Full Text] [Related]
11. Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein.
Fischer H; Ullah M; de la Cruz CC; Hunsaker T; Senn C; Wirz T; Wagner B; Draganov D; Vazvaei F; Donzelli M; Paehler A; Merchant M; Yu L
Neuro Oncol; 2020 Jun; 22(6):819-829. PubMed ID: 32383735
[TBL] [Abstract][Full Text] [Related]
12. TRK Inhibition with Entrectinib in Metastatic Salivary Secretory Carcinoma (SC): A Case Report.
Ernst MS; Lysack JT; Hyrcza MD; Chandarana SP; Hao D
Curr Oncol; 2022 May; 29(6):3933-3939. PubMed ID: 35735423
[TBL] [Abstract][Full Text] [Related]
13. From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis.
Cui Z; Zhai Z; Xie D; Wang L; Cheng F; Lou S; Zou F; Pan R; Chang S; Yao H; She J; Zhang Y; Yang X
Front Pharmacol; 2024; 15():1329409. PubMed ID: 38357305
[No Abstract] [Full Text] [Related]
14. Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications.
Krebs MG; Blay JY; Le Tourneau C; Hong D; Veronese L; Antoniou M; Bennett I
ESMO Open; 2021 Apr; 6(2):100072. PubMed ID: 33676294
[TBL] [Abstract][Full Text] [Related]
15. Site-agnostic biomarker-guided oncology drug development.
Jørgensen JT
Expert Rev Mol Diagn; 2020 Jun; 20(6):583-592. PubMed ID: 31813299
[TBL] [Abstract][Full Text] [Related]
16. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
Sartore-Bianchi A; Pizzutilo EG; Marrapese G; Tosi F; Cerea G; Siena S
Expert Rev Anticancer Ther; 2020 May; 20(5):333-341. PubMed ID: 32223357
[No Abstract] [Full Text] [Related]
17. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs MG; Shaw AT; de Braud F; Rolfo C; Ahn MJ; Wolf J; Seto T; Cho BC; Patel MR; Chiu CH; John T; Goto K; Karapetis CS; Arkenau HT; Kim SW; Ohe Y; Li YC; Chae YK; Chung CH; Otterson GA; Murakami H; Lin CC; Tan DSW; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Doebele RC;
Lancet Oncol; 2020 Feb; 21(2):261-270. PubMed ID: 31838015
[TBL] [Abstract][Full Text] [Related]
18. Economic Evaluation of a Tumour-Agnostic Therapy: Dutch Economic Value of Larotrectinib in TRK Fusion-Positive Cancers.
Michels RE; Arteaga CH; Peters ML; Kapiteijn E; Van Herpen CML; Krol M
Appl Health Econ Health Policy; 2022 Sep; 20(5):717-729. PubMed ID: 35843997
[TBL] [Abstract][Full Text] [Related]
19. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers.
Drilon A; Tan DSW; Lassen UN; Leyvraz S; Liu Y; Patel JD; Rosen L; Solomon B; Norenberg R; Dima L; Brega N; Shen L; Moreno V; Kummar S; Lin JJ
JCO Precis Oncol; 2022 Jan; 6():e2100418. PubMed ID: 35085007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
